Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib and Cobimetinib as a Redifferentiation Strategy in High-Risk, RAI Naïve, BRAFV600E Mutated Differentiated Thyroid Carcinoma
NCT06440850Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Jul 2024
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and cobimetinib in differentiated thyroid carcinoma (DTC), sponsored by City of Hope. Primary endpoint: Proportion of patients who achieve excellent or indeterminate response at 6 weeks. Started Jul 2024; status: recruiting.
02
Drugs
vemurafenibcobimetinib
03
Conditions
differentiated thyroid carcinoma (DTC)
Beyond the preview
Go deeper on NCT06440850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06440850.